American Association for Cancer Research
ccr-23-0290_supplementary_figure_s1_suppfs1.pdf (1.31 MB)

Supplementary Figure S1 from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis

Download (1.31 MB)
journal contribution
posted on 2023-11-01, 07:21 authored by Ben Yi Tew, Alex J. Kalfa, Zeyi Yang, Kyle M. Hurth, Thomas Simon, Eric Abnoosian, Stephen T. Durant, Petra Hamerlik, Bodour Salhia

Supplemental Figure 1. Immunochemistry (IHC) staining of γH2AX at experimental endpoint





Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated inhibitor, as a radiosensitizer for breast cancer CM treatment. Three patient-derived xenograft (PDX) tumors including 2 HER2+ and 1 triple-negative breast cancer harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain. Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared with 123 days in controls. Administration of AZD1390 posttreatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50 to 100 days posttreatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment. Our results demonstrate that AZD1390 effectively sensitizes breast cancer CM to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CM.

Usage metrics

    Clinical Cancer Research





    Ref. manager